Cevenfacta Európai Unió - magyar - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihaemorrhagiás - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Kogenate Bayer Európai Unió - magyar - EMA (European Medicines Agency)

kogenate bayer

bayer ag  - octocog alfa - hemofília a - antihaemorrhagiás - a vérzés kezelése és megelőzése az a haemophilia (veleszületett viii faktor hiány) betegeknél. ez a készítmény nem tartalmaz von willebrand-faktort, ezért nem javallott a von willebrand-féle betegség.

Galvus Európai Unió - magyar - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptin - diabetes mellitus, 2. típus - cukorbetegségben szedett gyógyszerek - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra Európai Unió - magyar - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptin - diabetes mellitus, 2. típus - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5. és 5. sz. 1 a rendelkezésre álló adatokra a különböző kombinációk esetén).

Xiliarx Európai Unió - magyar - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - diabetes mellitus, 2. típus - cukorbetegségben szedett gyógyszerek - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5. és 5. sz. 1 a rendelkezésre álló adatokra a különböző kombinációk esetén).